Amneal Pharmaceuticals (AMRX) Other Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals' Other Non Operating Income history runs 10 years deep, the most recent figure standing at -$7.8 million for Q1 2026.

• In Q1 2026, Other Non Operating Income fell 283.66% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$30.1 million (down 399.14% YoY), while the FY2025 annual figure was $16.5 million, changed N/A from the prior year.
• Other Non Operating Income was -$7.8 million for Q1 2026 at Amneal Pharmaceuticals, down from $7.4 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $7.4 million in Q4 2025 to a low of -$31.4 million in Q3 2025.
• Historically, Other Non Operating Income has averaged $389764.7 across 5 years, with a median of $2.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Other Non Operating Income soared 19786.21% in 2022, then tumbled 1479.29% in 2025.
• A 5-year view of Other Non Operating Income shows it stood at $3.7 million in 2022, then tumbled by 38.06% to $2.3 million in 2023, then slumped by 135.62% to -$815000.0 in 2024, then jumped by 1014.11% to $7.4 million in 2025, then sank by 204.7% to -$7.8 million in 2026.
• The last three Other Non Operating Income figures came in at -$7.8 million (Q1 2026), $7.4 million (Q4 2025), and -$31.4 million (Q3 2025), per Business Quant data.